The invention relates to virosome-based influenza vaccines for the manufactureof medicaments that are administered intradermally in humans. The inventionprovides (trivalent) compositions comprising low doses of hemagglutinin (HA)antigen in a virosomal preparation that fulfill the immune response standardswith respect to seroconversion rates, GMT-fold increase and protection rates,for use in vaccination set-ups.
